Charlene Liao, Immune-Onc Therapeutics Inc.’s CEO told BioWorld she has a solid plan for using the company’s new $73 million series B1 and B2 financing. “It is time to go beyond T cells and to consider myeloid checkpoints as the next wave of cancer immunotherapies,” she said. Immune-Onc will use the funding to target myeloid checkpoints, especially leukocyte immunoglobulin-like receptor subfamily B, as it continues to develop its blood cancer and solid tumor therapies.
Pyxis Oncology Inc., a company building a portfolio of antibody-drug conjugates (ADCs) and immunotherapies for cancer, has closed a $152 million series B financing co-led by Arix Bioscience and RTW Investments LP. The fresh funds will help the company advance multiple ADC candidates in-licensed from Pfizer Inc. and Legochem Biosciences Inc. as well as its discovery-stage pipeline, CEO Lara Sullivan told BioWorld. The ADCs are expected to move to the clinic in 2022.
It’s a first for Larry Miller. In his 30 years of working in pharma, he has never run a company that didn’t have a pack of near competitors scrambling to develop a therapy. “Not even close,” he told BioWorld. Miller, the CEO of Apnimed Inc., just saw the company close on a $25 million series B to help drive its lead program, a once-daily, oral obstructive sleep apnea (OSA) therapy, into a phase III registrational trial.
DUBLIN – Step Pharma SAS closed a €35 million (US$41.5 million) series B round to move its first-in-class cytidine triphosphate synthase 1 inhibitor into clinical trials in patients with T-cell and B-cell malignancies.
LONDON – Targeted protein degradation (TPD) specialist Amphista Therapeutics Ltd. has delivered yet another demonstration of investor interest in the field, closing a $53 million series B.
Chinese eye disease specialist Arctic Vision Biotechnology Co. Ltd. raised more than $100 million in a series B financing round. The clinical-stage company will use the funds to initiate a phase III trial for its core asset, ARVN-001 (triamcinolone acetonide suprachoroidal injectable suspension), for uveitic macular edema in China this year.
Strive Health LLC has raised $140 million in a series B funding round led by Capitaig, Alphabet’s independent growth fund. The round also includes Redpoint Ventures, and current investors NEA, Town Hall Ventures, Ascension Ventures, and Echo Ventures. This funding round brings the Denver-based kidney care company’s total funding to $223.5 million.
Only four years after its foundation, Acepodia Inc. raised $47 million in a series B financing round. The funds will help the oncology company move its first cell therapy candidate to phase II trials, while expanding its research and development activities with other products from its tech platform.
Chinese eye disease specialist Arctic Vision Biotechnology Co. Ltd. raised more than $100 million in a series B financing round. The clinical-stage company will use the funds to initiate a phase III trial for its core asset, ARVN-001 (triamcinolone acetonide suprachoroidal injectable suspension), for uveitic macular edema in China this year.
DUBLIN – Agomab Therapeutics NV raised $74 million in a series B round that attracted two heavyweight U.S. crossover investors, Redmile Group, which led the financing, and Cormorant Asset Management.
RSS
